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Abstract
CADASIL is the most common hereditary cause of repeated ischemic strokes, and has also been identified as a model of
pure vascular dementia. The objective of this study was to establish the cognitive performance of asymptomatic carriers
with the mutations R1031C and R141C. This observational cross-sectional analytical study divided subjects into three
groups: asymptomatic carriers of the R1031C mutation (𝑛 = 39), asymptomatic carries of the R141C mutation (𝑛 = 8)
and non-carriers (𝑛 = 50). Statistically significant differences were found (𝑝 < 0.05) between the group of the R1031C
mutation and the non-carriers in constructional praxis, executive function and abstract reasoning. For the R141C
mutation, scores below expected values in executive function and mental calculation were observed. It is concluded
that asymptomatic carriers of the two mutations showed low performance in working memory, mental abstraction and
processing speed, which could be associated with preclinical cognitive biomarkers preceding the presentation of the
first vascular event.
Resumen
La Arteriopatía Cerebral Autosómica Dominante con Infartos Subcorticales y Leucoencefalopatía (CADASIL), es
producida por mutaciones en el gen NOTCH3, es la causa hereditaria más común de accidentes cerebrovasculares
isquémicos repetidos. Objetivo: establecer el desempeño cognitivo en portadores asintomáticos con las mutaciones
R1031C Y R141C. Método: estudio observacional, analítico transversal. Se dividieron en tres grupos: portadores
asintomáticos con mutación R1031C (𝑛 = 39), asintomáticos con mutación R141C (𝑛 = 8) y no portadores (𝑛 =
50). Resultados: se encontraron diferencias estadísticamente significativas (𝑝 < 0.05) entre el grupo de portadores
asintomáticos de la mutación R1031C y los no portadores en praxias construccionales, función ejecutiva y razonamiento
abstracto. En la mutación R141C, se observaron puntuaciones bajas en función ejecutiva y cálculo mental. Conclusiones:
los portadores asintomáticos de las dos mutaciones evidenciaron bajo rendimiento en memoria de trabajo, abstracción
mental y velocidad de procesamiento, pudiendo estar asociados como biomarcadores cognitivos preclínicos, antes del
primer evento vascular o los primeros síntomas.
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1. Introduction
Autosomal Dominant Cerebral Arteriopathy with Sub-
cortical Infarcts and Leukoencephalopathy (CADASIL)
was first cited in 1991 by Tournier-Lasserve, Iba-Zizen,
Romero, and Bousser (1991), who described the disease
as having an autosomal dominant pattern based on the
index case of a 50-year-old man with aphasia and severe
headache (nausea and photophobia) who developed pseu-
dobulbar palsy, dysarthria and the inability to walk as
well as presenting depression and apathy before finally
developing dementia. After investigation, the authors
were able to associate these phenotypic traits to similar
cases found in Spain since 1970, and named the disease
using the acronym CADASIL (López & Vilanova, 2009;
Tournier-Lasserve et al., 1991).
CADASIL is a type of multi-infarct vascular demen-
tia caused by mutations in the NOTCH3 (Neurogenic
locus notch homolog protein 3) gene, located in the short
arm of chromosome 19. This gene codifies a transmem-
brane receptor (N3) of 2321 amino acids. Similar to
other NOTCH receptors, NOTCH3 is synthesized as a
complete protein, which suffers a proteolytic rupture (S1
rupture) by furine, generating two domains: the extra-
cellular N-terminal domain (N3ECD, 210 kDa) and an
intracellular terminal (N3ICD)(Tikka et al., 2014). The
main functions of these are during organogenesis, includ-
ing vascular genesis, stem cell renewal, cell proliferation,
cell fate determination, and differentiation and apop-
tosis (Joutel et al., 2000; Prakash, Hansson, Betsholtz,
Mitsiadis, & Lendahl, 2002).
This disease is hereditary in nature, with an autoso-
mal dominant pattern, and is characterized by transient
ischemic attacks (85%), migraine with aura (41%), and
cognitive (50%) or psychiatric (20−41%) impairment,
with a high prevalence of depression and apathy, as well
as occasionally epilepsy (10%) (López & Vilanova, 2009).
The progression of the disease leads to a major neu-
rocognitive disorder of subcortical nature, neurological
dysfunctions such as dysarthria, pseudobulbar palsy, and
hemiparesis, and finally death, coming generally 15-25
years after the first symptoms appear. Young adults
of both sexes are affected (Di Donato et al., 2017; We-
sołowski, Dziewulska, Koziarska, & Iżycka-Świeszewska,
2015).
With regard to its cognitive profile, CADASIL has
a clinical evolution different to that of other forms of
dementia, making it important to specify the cognitive
function supporting the differential diagnosis. In this
respect, (Dichgans, 2009) demonstrated that this pathol-
ogy creates a deficit in processing speed and executive
functions, low verbal fluency, and concentration prob-
lems while episodic memory is preserved. In general,
people with this disease present lapses both in immedi-
ate free recall and long-term memory, but recognition is
preserved even in the case of elderly people and those
in the moderate stage of the disease, suggesting that
the encoding process is preserved even as the disease
progresses (Di Donato et al., 2017). Cognitive deficit
reduces significantly with age, while impairments appear
to instrumental and verbal activities, visual memory,
reasoning and spatial skills (Buffon et al., 2006).
On another note, the results of neuropsychological
tests of all the cognitive processes significantly corre-
late with the number of lacuna infarcts. A recent study
demonstrated that the incidence of dementia in CADASIL
is associated with the number of recurrent CVAs (Chabriat
et al., 2016). However, few research projects have man-
aged to identify the relevant cognitive markers including
those prior to the first CVA, although a slowdown in
information processing and working memory have been
observed (Brookes, Hollocks, Tan, Morris, & Markus,
2016).
It is estimated that there are around 500 families with
CADASIL worldwide, in which more than 200 different
mutations of NOTCH3 have been described, confirming
high genetic heterogeneity. There is great variability
in the phenotype even between members of the same
family (Dziewulska, 2009; Rutten et al., 2016). Nonethe-
less, few studies have focused on the identification and
differentiation of the cognitive profile of each of these
mutations, although the discrimination between them
is important in clinical analysis. In Colombia in 2010,
a genotype-phenotype was correlated in carriers of the
R1031C and C455R mutations, with the conclusion that
the participants with the R1031C mutation presented
greater cognitive impairment and dementia, while with
the C455R mutation, the age of onset was lower but
cognitive deterioration was slower and less aggressive
(Moreno et al., 2010).
Meanwhile, the R141C mutation described in this
article has a prevalence of 15% in the European popula-
tion, yet there have been few studies on people with this
mutation. Only five related studied were found in the
database consulted (PubMed). In Japan, while multiple
families with CADASIL have been identified, to date
only two subjects with the R141C mutation, unrelated
to each other, have been described (Mizuno, Mizuta, &
Tomimoto, 2016; Murakami et al., 2001; Önder, Kurtcu,
Arsava, & Topcuoglu, 2017; Yadav, Bentley, Srivastava,
Prasad, & Sharma, 2013).
In India, a family with CADASIL has emerged for
the first time with 17 individuals spanning 3 compatible
generations, of which 5 members have been confirmed
as having this mutation (Yadav et al., 2013). Finally, in
Önder et al. (2017) reported that the R141C mutation
is uncommon, adding that only two research projects on
the mutation had been carried out in the country: a case
study in 2014 and a report on two individuals in 2017.
In Colombia no descriptions exist of the cognitive
genotype-phenotype of the R141C mutation. This study
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is the first to create such a description, and moreover,
has a robust sample size, larger than those previously re-
ported in respect to other mutations linked to CADASIL.
Considering the above, this study aims to establish
the cognitive performance of a group of asymptomatic
carriers belonging to families in the department of An-
tioquia with the R1031C and R141C mutations of the
NOTCH3 gene. In addition, it aims to compare the neu-
ropsychological profile of people with the R1031C with
that of a group of non-carriers. To achieve this objective,
a key task is the implementation of neuropsychological
batteries able to rapidly identify the cognitive dissoci-
ation of CADASIL and with enhanced discriminatory
power through the use of evaluative measures that al-
low subtle changes to be detected even in asymptomatic
patients.
2. Method
2.1 Research Type and Design
An observation, cross-sectional, and analytical study was
performed, comparing the cognitive performance of a
group of asymptomatic carriers of the R1031C mutation
with that of a group of non-carrier subjects belonging
to the same CADASIL families. Additionally, a group
of carriers of the R141C mutation was compared to
neuropsychological scales established in the normal pop-
ulation. Each participant was evaluated after providing
informed, written consent. This project was approved by
the Bioethics Committee of the University of Antioquia.
2.2 Participants
The participants in this study were asymptomatic carriers
belonging to CADASIL families in Antioquia (Colom-
bia). They had Functional Assessment Staging (FAST)
and Global Deterioration Scale ratings between 1 and 2
and no history of CVA. The participants were contacted
using information on the SISNE database of the Neuro-
sciences Group of the University of Antioquia Research
Center (SIU). Participants were selected based on inclu-
sion criteria after neurological and neuropsychological
evaluation. DNA extraction was carried out for all mu-
tations following the SIU procedure, with a test termed
“PCR RFLP” using restriction enzyme digestion, and
visualized in agarose gel.
The exclusion criteria were: subjects with a prior
neurological illness other than CADASIL, a history of
psychiatric illness or non-controlled systemic disease, or
illiteracy, which would prevent them from carrying out
the neuropsychological evaluation.
The study was double blind; neither the participants
nor the investigators were aware of the genetic status of
the subjects, and therefore could not distinguish between
the carrier and non-carrier groups. Simple random sam-
pling was performed using the SISNE platform, a process
carried out by a systems engineer able to access and iden-
tify the carrier and non-carrier groups. Subsequently,
subjects were divided into three groups according to their
genotyping. The first group was composed of 39 asymp-
tomatic carriers with the R1031C mutation; the second
of 8 asymptomatic carriers of the R141C mutation; and
the third of 50 healthy individuals without the mutations
affecting the CADASIL families.
2.3 Materials
The following procedures were performed with each par-
ticipant over two sessions:
Medical evaluation: Personal and family history, med-
ical examination with an emphasis on neurological symp-
toms, behavioral evaluation, and application of neuropsy-
chiatric scales (Cummings Neuropsychiatric Inventory
[NPI], Clinical Dementia Rating [CDR] and application
of dementia criteria from the Diagnostic and Statistical
Manual of Mental Disorders [DSM - IV]).
Neuropsychological evaluation: A neuropsychological
evaluation protocol involving assessment of all cogni-
tive domains was applied, using guidelines validated in
Colombia by the Neurosciences Group of the University
of Antioquia. This included the following set of tests
developed by the Consortium to Establish a Registry
for Alzheimer’s Disease [CERAD-col]: Verbal fluency
test- animals, Boston Naming Test (abbreviated format),
Mini-Mental State Examination [MMSE], word list (re-
call and recognition of words on a list), constructional
praxis (copying and recall), digit symbol, Trail Making
test part A [TMT A], Raven test part A, verbal fluency
test, phonological fluency test, Rey Osterrieth figure test,
WAIS arithmetic test and Wisconsin Card Sorting test,
modified version by the neurosciences group (Arboleda
et al., 2010).
In addition, functionality and severity scales were
applied including Functional Assessment Staging [FAST],
the Global Deterioration Scale [GDS], Barthel (Mahoney
& Barthel, 1965), Katz (Katz, 1963) and Lawton-Brody
(Lawton & Brody, 1969). To evaluate memory com-
plaints, the questionnaire was applied to the patient and
family member, while for the emotional state evaluation,
the abbreviated form Yesavage depression scale was used
(Yesavage et al., 1982).
Following the recommendations of the studies car-
ried out in Colombia described above, it was decided
to broaden the battery with respect to the evaluation
of executive function, which includes the following neu-
ropsychological evaluation instruments:
2.4 Statistical Analysis
The SPSS 24 statistical package was used to analyze ob-
tained data. The statistics were used based on the nature
of the variables. For quantitative variables, averages and
standard deviations were obtained. The qualitative vari-
ables were analyzed in terms of frequency measurements
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Table 1
Additional Neuropsychological evaluation instruments.
Neuropsychological Test Cognitive Domain Reference
Forward order number retention Attention Wechsler, 1987
Free and cued selective
Memory
Grober, Buschke, & Korey, 1987
reminding test [FCSRT]
Trail Making Test B - Time
Executive Function
Reitan y Wolfson, 1985
Ineco Frontal Screening [IFS], Torralva, Roca, Gleichgerrcht,
& López, 2009
STROOP Golden, 1976
Backwards order number retention Wechsler, 1987
Letter and number sequencing Wechsler, 1987
Matrices Abstract Reasoning Wechsler, 1987
Geriatric Anxiety Scale Functionality Pachana et al., 2007
Scale
and percentages. To establish the relationship with socio-
demographic variables, a chi squared (x2) test was used,
and to observe the differences in the performance of the
cognitive tasks of each group, the Mann-Whitney non-
parametric U test was used. A statistical significance
level of 𝑝 < 0.05 was used.
3. Results
With respect to the demographic variables, it was found
that the majority of the participants were women, with
no significant differences being presented between asymp-
tomatic carriers of the R1031C mutation (56.4%) and
the non-carriers (66%). The results for education level
showed that the carrier group had a median of 7 (medium
education level), and the non-carrier group had a median
of 5 (low education level), without significant differences
being found between the groups. With regard to age,
the asymptomatic carriers had a median age of 29 and
the non-carriers 30 (see Table 2).
Comparison of the results of the neuropsychological
tests of the asymptomatic carriers with mutation R1031C
(𝑛= 39) group and the non-carriers (𝑛= 50), found statis-
tically significant differences (𝑝 < 0.05) in constructional
praxis cognitive processes of when copying the Rey Os-
terrierth figure (𝑝 = .010); for executive function in the
INECO backwards digit span subtest (𝑝 = .023); INECO
total (𝑝= .024); INECO working memory scale (𝑝= .011);
and in the WAIS reverse order number retention subtest
(𝑝 = .035). Similarly, statistically significant differences
were found for abstract reasoning in the WAIS subtest
matrices (𝑝 =,029), with better cognitive performance
observed in the carrier group with R1031C mutation,
which is consistent with expectations for this population
(see Table 3).
With regard to the demographic characteristics of the
group of 8 asymptomatic carriers of the R141C mutation,
75% were women (in this regard there are no studies
showing sex differences in the execution of the tests).
The median education level was 7 (low level) and the
median age was 37 (see Table 4).
Considering the neuropsychological results of the
asymptomatic carriers with the R141C mutation, the
cognitive performance of the group was described with
respect to the Colombian scales validated for a normal
adult population. The results for the MMSE general
cognitive state evaluation showed an average of 28.13
points, while in the normal population the estimated
average is 28.47 points with a standard deviation of 1.49.
In tests evaluating the different cognitive domains, scores
below those expected for the age range were observed for
executive function (processing speed and working mem-
ory). In the Stroop word test (𝑛 = 3) the average score
was 99 points compared to a standardized average of 33.1
points with a standard deviation of 11.2 for the normal
population; and in the Stroop color test the average score
was 58.50 points compared to an estimated average of
44.8 with a standard deviation of 12.6 points for the av-
erage population; while mental calculation assessed with
the WAIS arithmetic subtest (𝑛 = 8) showed an average
score of 5 points compared to the validated Colombian
average of 7.7 points with a standard deviation of 1.8.
Finally, the total INECO score (𝑛 = 3) results for the
asymptomatic carriers of this mutation were below the
expected level with an average of 24 points, while the
baseline for the normal population is 26 points. While
the scores for the TMT-A time and digit symbol tests
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Table 2
Demographic characteristics of the asymptomatic carriers of the R1031C mutation group and the
non-carrier group.
R1031C (𝑛 = 39) Non-carriers (𝑛 = 50)
𝑁(%) 𝑁(%) 𝑐2 𝑎 𝑝 Value
Sex
Male 17(43.6) 17(34) 1.411 0.49
Female 22(56.4) 33(66)
Med (IR) Med (IR) 𝑈𝑏 𝑝 Value
Education Level 7(7) 5(6) 898 0.516
Age 29(14) 30(12) 955.5 0.87
Note: Med=Median; IR=Interquartile Range, the sign (+) indicates fo > fe. 𝑎 Pearson Chi squared; 𝑏
Mann-Whitney U ∗∗∗𝑝 < 0.001
were not statistically significant, in the graph, longer
time and lower performance can nonetheless be observed
for the execution of these tests (see Graph 1).
4. Discussion
Returning to prior CADASIL studies in Colombia, in
2000,two families from Antioquia department carrying
the R1031C and C455R mutations of the NOTCH3 gene
were reported for the first time (Lopera et al., 2000). In
2007 another article was published that monitored the
cognitive characteristics of these two mutations. This
concluded that no differences were found between the
subjects evaluated as they were young and asymptomatic,
that cognitive decline over time was not expected and
that a monitoring period of four years was not ade-
quate to determine significant evolution in cognitive al-
ternations. The article added that more sensitive tools
were required for neuropsychological evaluation (Henao-
Arboleda, Aguirre-Acevedo, Pacheco, Yamile-Bocanegra,
& Lopera, 2007). Finally, in 2010 an analytical study was
carried out in order to determine the genotype-phenotype
in this population, concluding that the R1031C mutation
presented greater cognitive impairment and dementia,
while carriers with the C455R mutation showed an earlier
age for the onset of cognitive decline, although decline
was slower and less aggressive (Moreno et al., 2010).
With respect to the mutations reported, it is impor-
tant to clarify that people with the C455R mutation are
not included in the present study, as they did not fulfill
the criteria. However, this study is the first to describe
the R141C mutation, with no prior reports on this in
Colombia and only a few case studies worldwide on sub-
jects from Europe, India, Turkey and Japan (Mizuno et
al., 2016; Murakami et al., 2001; Önder et al., 2017). The
cognitive profile of this mutation has not been described
previously.
In the present study, cognitive analysis was per-
formed of 97 asymptomatic subjects with and without
the NOTCH3 gene mutation. When 39 asymptomatic
carriers of the R1031C mutation were compared to a
group of 50 non-carriers from the same CADASIL fami-
lies (the participants in these two groups being mainly
women) no statistically significant differences were found
between carriers and non-carriers. Regarding education
level, the two groups presented similar characteristics,
which could be related to the cultural and economic cir-
cumstances of the subjects, who come from rural areas
of the department of Antioquia. It is important to high-
light this information as the two groups presented similar
demographic characteristics, facilitating analysis of the
information.
The results demonstrated significant differences be-
tween the asymptomatic carrier group with the R1031C
mutation and the non-carriers in cognitive tests evaluat-
ing constructional praxis and abstract reasoning, with
inferior cognitive performance observed in the carrier
group.
Considering the results of this mutation in construc-
tional praxis, while there were statistically significant
differences in copying the Rey Osterrierth figure, this
study does not suggest constructional apraxia. These
results may instead be due to executive shortcomings,
specifically with the construction type in the execution
of the figure (planning and organization).
Meanwhile, the following INECO components showed
significant results for executive function: backwards digit
span, working memory scale, and total test score. This
suggests that the R1031C carriers presented deficiencies
in providing temporal information and in manipulating
complex cognitive tasks (working memory). INECO was
used because it has been shown to be a battery able to
rapidly identify cognitive dissociations with increased dis-
criminatory power in pre-symptomatic patients, and has
demonstrated high sensitivity in 96.2% of cases, speci-
ficity in 91.5%, and predictive value (Torralva, Roca,
Gleichgerrcht, Lopez, & Manes, 2010).
The study differs from most investigations, which
refer to executive dysfunction occurring from the time of
CVA recurrence, in that slight alterations were observed
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Table 3
Results of the neuropsychological tests. Comparison between asymptomatic carriers of the R1031C
mutation and non-carriers.
R1031C (𝑛 = 39) Controls (𝑛 = 50)
Function/test Med (RI) Med (RI) 𝑈𝑎 𝑝 value
Mini-mental 29(3) 29(2) 860 0.317
ATTENTION
Digits and symbols-cued 48(29) 42.5(21) 228.5 0.791
Forward order number retention 7(2) 7(2) 188.5 0.228
MEMORY
Word list total (CERAD) 18(6) 18(5) 895 0.507
Total Intrusions 0(1) 0(1) 919 0.602
Word list evocation 7(3) 6(3) 918 0.631
Recognition 10(1) 10(1) 961 0.885
Praxial construction evocation (CERAD) 8.50(3) 8(4) 880 0.428
Osterrierth Figure evocation 15.50(10) 14.25(10) 866.5 0.369
FCSRT free 1 10(2) 10(3) 229.5 0.806
FCSRT cued 1 15.50(1) 16(1) 212 0.463
FCSRT free 2 12(2) 13(2) 201 0.356
FCSRT cued 2 16(0) 16(0) 220.5 0.441
FCSRT free 3 15(1) 14(2) 177 0.133
FCSRT cued 3 16(0) 16(0) 221.5 0.430
FCSRT delayed free 15(3) 14(2) 167.5 0.087
FCSRT delayed cued 16(0) 16(0) 216.5 0.354
PRAXES
Constructional Praxis (CERAD) 10(2) 10(2) 793.5 0.117
Rey Figure 25(7) 29.25(8) 662.5 ∗0.010
LANGUAGE
Verbal Fluency 16(7) 16(5) 927 0.69
Boston Naming (CERAD) 12(2) 13(2) 966.5 0.943
EXECUTIVE FUNCTION
Phonological Fluency ”F” 10(8) 8.50(6) 816.5 0.326
Wisconsin success 20(10) 21(9) 0.252 0.252
Wisconsin categories 2(2) 2(1) 0.895 0.895
Wisconsin perseverance 19(9) 17(9) 0.299 0.299
Trail Making Test A - Time 70(49) 67(22) 822.5 0.353
Trail Making Test B - Time 143.5(95) 120.5(105) 158,5 0.94
INECO Backwards digits 4(2) 5(2) 144.5 ∗
INECO Total 22(6) 24(4) 153 ∗0.024
INECO Working memory scale 5(2) 7(2) 132.5 ∗0.011
STROOP Word 90(31) 82(28) 225 0.729
STROOP Color 59(16) 59(11) 210 0.488
STROOP Color-Word 32(22) 33(12) 209 0.474
Backwards order number retention 4(2) 5(2) 151 ∗0.035
Letter and number sequence 7(5) 8(4) 174 0,215
ABSTRACT REASONING
Raven 9(1) 9(3) 929 0,986
Matrices 6(6) 9.50(8) 146 ∗0,029
MENTAL CALCULATION
Arithmetic 9(2) 7(5) 815 0.389
SCALES
QF 2(8) 5(7) 73.5 0,166
QP 7(13) 11(16) 788 0.221
Yesavage 1.50(4) 3(6) 827.5 0.294
Geriatric Anxiety Scale 1(8) 2.50(8) 202.5 0.377
Note: Med=Median; IR=Interquartile Range, 𝑎 Mann-Whitney 𝑈 ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001
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Figure 1. Neuropsychological characteristics of asymptomatic carriers of the R141C mutation. Colombian scale for
normal population.
Table 4
Demographic characteristics of a group of 8 asymp-
tomatic patients with the R141C mutation.
R141C (𝑛 = 8)
𝑁(%)
Sex
Male 2(25)
Female 6(75)
Note: Med=Median; IR=Interquartile Range, the sign
(+) indicates fo > fe. 𝑎 Pearson Chi squared ∗∗∗𝑝 < 0.001
in the subjects evaluated. This is consistent with the work
of Amberla and Brookes, which indicates that subjects
with mutations in the NOTCH3 gene present alterations
to short term memory, working memory and executive
function even when in a preclinical state. From this it can
be inferred that cognitive deterioration precedes the first
ischemic event. Therefore, these cognitive characteristics
could be the first symptoms of CADASIL (Amberla et
al., 2004; Brookes et al., 2016).
Similarly, statistically significant differences were found
in tests measuring mental abstraction. Visuospatial func-
tions and reasoning have not been highly investigated in
the CADASIL context and those studies that mention
these skills refer to their preservation in the initial stages
of the disease. Therefore, the current study differs from
these and instead proposes deeper investigation into the
cognitive domain of executive functions (Dichgans, 2009).
Another cognitive test implemented in this study was
the FCSRT. This facilitates evaluation of memory encod-
ing and recall, as well as identifying false recognition and
intrusions. Although commonly used and demonstrated
to be highly specific in the context of Alzheimer’s dis-
ease, a study by Epelbaum et al. (2011). showed that a
third of those tested with CADASIL presented memory
deterioration according to the FCSRT (free recall), this
being the second most significant cause after alterations
in executive function (attention deficiencies and working
memory) (Epelbaum et al., 2011).
While in the current study the results for the FCSRT
were not statistically significant, it is suggested that
longitudinal studies be performed to demonstrate changes
in the performance of this cognitive process. It would be
expected that patients with NOTCH3 gene mutations
would gain higher scores for cued recall than for free
recall, suggesting that people with subcortical damage
present greater difficulty in information retrieval, while
those with cortical diseases present greater difficulties in
encoding (Epelbaum et al., 2011; Russo et al., 2013).
Regarding the neuropsychological results obtained
with the asymptomatic carrier group for the other eval-
uated mutation (R141C), the cognitive profile was de-
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scribed using the scale used for the Colombian population
in the neuropsychological evaluation protocol established
by the Neurosciences Group of the University of Antio-
quia. This can be used for diagnosis, monitoring, orolder
people, comparison with others with or without cognitive
impairment (Arboleda et al., 2010).
In these tests, asymptomatic carriers of the R141C
mutation presented an average of 28.13 points in the
MMSE general cognitive state evaluation, with the aver-
age score for the normal population estimated as 28.47
with a standard deviation of 1.49 points. This indicates
that the average global cognitive performance was within
the expected range, which is expected in the case of
healthy participants, as MMSE results in initial stages
tend to be normal. For this reason, this study was too
short to evaluate cognitive decline in the initial stages
of this pathology (do Campo Vázquez, Morales-Vidal,
Randolph, Chadwick, & Biller, 2011).
In tests evaluating the different cognitive domains,
scores below those expected were observed for executive
function in the INECO, Stroop word and Stroop color
tests. In the evaluation of mental calculation, scores be-
low those expected were obtained in the WAIS arithmetic
sub-test. This suggests that in the sample group there
were cases of slow information processing and executive
and working memory dysfunction, something that is not
well described in the literature and is still being explored
as an initial symptom in asymptomatic subjects with
NOTCH3 mutations (Amberla et al., 2004).
In addition, the results obtained in the Stroop tests
(color and word) correspond to those reported by Vazquez
et al., who indicate that subjects with CADASIL present
speed reductions intime-controlled tasks, a slowdown
that also affects abstract reasoning (a difficulty found in
the R1031C mutation) (do Campo Vázquez et al., 2011).
In conclusion, this study differs from previous investi-
gations where findings suggested that asymptomatic sub-
jects with NOTCH3 mutations, the presence of leukoen-
cephalopathy and no CVA history do not predict alter-
ations in cognitive performance (Torralva et al., 2010). In
contrast, it supports studies that link frontal subcortical
patterns with greater executive impairment, although as
the disease advances and cognitive impairment worsens,
the cerebral cortex also tends to be affected in CADASIL
due to cortical micro infarcts or as a result of degener-
ation, which in studies of more advanced stages of the
disease cause deterioration in memory (Di Donato et al.,
2017).
The results of this study improve our understand-
ing of the cognitive characteristics that differentiate a
diagnostic group with the R1031C mutation to one with
the R141C mutation, the neuropsychological character-
istics of which are still being explored. Although both
groups showed cognitive impairment, there were differ-
ences. Asymptomatic carriers of the R1031C mutation
showed alteration in constructional praxis (planning and
organization), working memory and mental abstraction
compared to the control group. Meanwhile, asymp-
tomatic carriers of the R141C mutation showed greater
impairment of processing speed and operative memory,
as well as executive dysfunction.
According to the information and studies described
above, this study produces results that support indica-
tions that asymptomatic carriers of NOTCH3 mutations
tend to present a greater deterioration in working mem-
ory and processing speed, suggesting that these changes
are possible cognitive markers in CADASIL. For this
reason, further investigations are proposed into clinical
aspects that could predict the disease, as well as the use
of controlled cognitive tests with event-related potentials
measuring processing speed, reaction times and oddball
paradigms, and the evaluation of Craik and Lockart
processing level memory paradigms.
Finally, it is of paramount importance to mention that
the ideal moment to begin the treatment of any neurode-
generative disease is before the appearance of clinical
symptoms. Considering that CADASIL is considered
to be the most common hereditary cause of recurrent
ischemic strokes and is identified as a model of pure
vascular dementia, it is ideal for study. Moreover, the
families with CADASIL found in Colombia make up one
of the most numerous groups on a global level.
Limitations
For future studies, it is suggested that the sample
size be broadened to facilitate more rigorous parametric
analyses that would allow inferences to be made and
more precise differences obtained.
With regard to the R141C mutation, deeper knowl-
edge is required in terms of its pathology in order to
understand the possible structural differences that would
allow it to be clearly distinguished from other NOTCH3
mutations.
The INECO battery, despite proving to be a rapid
detection tool demonstrating sensitivity in the perfor-
mance of cognitive analyses of asymptomatic subjects
for both mutations, is not validated for the Colombian
population.
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